GlassScriptPhysician profile
Nissrin Barade
NPI 1457943557
$1,314.91
in general payments reported to CMS, 2019-2025
19 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.22 · 2023: $312 · 2024: $614 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $344.49 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $172.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $144.57 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $114.89 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $77.11 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $67.66 | 2024 | Ibsrela |
| Exact Sciences Corporation | $65.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.33 | 2024 | Trulance |
| Astrazeneca Pharmaceuticals LP | $46.23 | 2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $39.93 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $37.08 | 2023 | Verquvo, Belsomra |
| Amgen INC. | $26.41 | 2024 | Repatha, Otezla |
| Pfizer INC. | $24.39 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2025 | |
| Glaxosmithkline, LLC. | $19.81 | 2025 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.54 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $16.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.85 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nissrin Barade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.